Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Hong Kong Stock Exchange  >  Genscript Biotech Corporation    1548   KYG3825B1059

GENSCRIPT BIOTECH CORPORATION

(1548)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
08/04/2020 08/05/2020 08/06/2020 08/07/2020 08/10/2020 Date
15.98 16.52 16.6 16.44 16.4 Last
7570000 6211726 5331842 4118000 3499000 Volume
-3.50% +3.38% +0.48% -0.96% -0.24% Change
Financials (USD)
Sales 2020 326 M - -
Net income 2020 -167 M - -
Net Debt 2020 - - -
P/E ratio 2020 -24,5x
Yield 2020 -
Sales 2021 437 M - -
Net income 2021 -103 M - -
Net Debt 2021 - - -
P/E ratio 2021 -41,2x
Yield 2021 -
Capitalization 4 073 M 4 074 M -
Capi. / Sales 2020 12,5x
Capi. / Sales 2021 9,32x
Nbr of Employees 3 738
Free-Float 54,4%
More Financials
Company
Genscript Biotech Corporation is a Hong Kong-based investment holding company principally engaged in life science research and related businesses. The Company operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell... 
More about the company
Surperformance© ratings of Genscript Biotech Corporat
Trading Rating : Investor Rating :
More Ratings
Latest news on GENSCRIPT BIOTECH CORPORAT
08/05GENSCRIPT BIOTECH : Voluntary announcement-research and development update
PU
08/02Legend names founder Frank Zhang as chief executive officer
RE
08/02GENSCRIPT BIOTECH : List of directors and their role and function
PU
08/02GENSCRIPT BIOTECH : Change of chief executive officer and redesignation of direc..
PU
07/23GENSCRIPT BIOTECH : Announces Publication of Clinical Data On New Method for Det..
PR
07/23GENSCRIPT BIOTECH : TRANSFER OF DISTRIBUTION ADSs AND DESPATCH OF CHEQUES FOR CA..
PU
05/29Legend Biotech Sets IPO at 18.4 Million ADSs; Sees Pricing at $18-$20 Each
DJ
05/14GENSCRIPT BIOTECH : Duke-NUS, GenScript and A*STAR launch first-in-the-world SAR..
AQ
04/07GENSCRIPT PROBIO : and Eutilex Enter into Exclusive Strategic Collaboration on P..
PR
03/09GENSCRIPT BIOTECH : Proposed spin-off of legend biotech corporation
PU
02/28Biotech group Novacyt announces deals for coronavirus test product
RE
02/11GENSCRIPT BIOTECH : Donates Protective Supplies to Fight Coronavirus, Calls for ..
PR
2019GENSCRIPT BIOTECH : Voluntary announcement - investment agreement with zhenjiang..
PU
2019GENSCRIPT BIOTECH : and Selecxine Enter Into Strategic Cooperation Agreement
PR
2019GENSCRIPT BIOTECH : China's Largest Plasmid and Virus Facility from GenScript wa..
PR
More news
News in other languages on GENSCRIPT BIOTECH CORPORAT
08/05GENSCRIPT BIOTECH : Voluntary announcement-research and development update
08/02Legend names founder Frank Zhang as chief executive officer
08/02GENSCRIPT BIOTECH : List of directors and their role and function
08/02GENSCRIPT BIOTECH : Change of chief executive officer and redesignation of direc..
07/23GENSCRIPT BIOTECH : Announces Publication of Clinical Data On New Method for Det..
More news
Chart GENSCRIPT BIOTECH CORPORATION
Duration : Period :
Genscript Biotech Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENSCRIPT BIOTECH CORPORAT
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 2,87 $
Last Close Price 2,12 $
Spread / Highest target 47,4%
Spread / Average Target 35,1%
Spread / Lowest Target 21,6%
EPS Revisions
Managers
NameTitle
Zhenyu Liu Chief Executive Officer
Ye Wang President, COO & Executive Director
Fang Liang Zhang Non-Executive Chairman
Jian Ge Meng Executive Director & VP-Investor Relations
Lu Quan Wang Non-Executive Director
Sector and Competitors